Tata's COVID-19 test kit to detect Omicron variant gets IMCR nod: All you need to know about 'OmiSure'

The new test, which will provide results in two-and-a-half hours, will most likely be sold in the market by around 12 January

FP Staff January 06, 2022 11:11:21 IST
Tata's COVID-19 test kit to detect Omicron variant gets IMCR nod: All you need to know about 'OmiSure'

Representational image. AFP

The Indian Council of Medical Research on Wednesday announced that it has approved a kit designed to detect the Omicron variant of coronavirus.

Here’s all we know about the new kit developed by Tata Medical and Diagnostics and how it will help amidst this wave of infections the country is witnessing owing to the new variant.

The Tata Medical and Diagnostics kit called 'OmiSure' can detect the Omicron variant of SARS-CoV2 in nasopharyngeal/oropharyngeal specimens during the RT-PCR tests. According to officials from the company, the test kit is compatible with all standard Real-Time PCR machines.

Dr V Ravi, head, Research & Development at Tata Medical & Diagnostic Centre, said that the kit uses the S Gene Target Failure (SGTF) strategy to detect the variant.

Explaining how the kit works, he was quoted as telling New Indian Express, "Globally, all other test kits for Omicron are either made for gene dropout or mutation specific detection. OmiSure is the first test kit combining both."

"On evaluation by the Indian Council of Medical Research (ICMR), it picked up all sequence samples with 100 percent accuracy. We have now received the licence from Central Drugs Standard Control Organisation (CDSCO) and will start production of OmiSure for commercial use within a week’s time," he added in the same report.

This kit can detect the Omicron variant as well as other variants of SARS-CoV2 reported so far. It has been reported that Tata officials have decided to fix the retail price of a kit at Rs 250 for the laboratory.

Dr V Ravi in an interview to Economic Times said that the company was looking to push out the kits to the market by around 12 January.

He added that the time from sample collecting to result generation it would take around two-and-a-half hours and could be reduced to 2.15 hours.

This would be highly beneficial owing to the fact that currently Omicron patients are detected only after genome sequencing. But this test can help eliminate that step and detection can be done during the testing.

A PTI report said that the kit will be manufactured by Tata MD at its Sriperumbudur facility in Tamil Nadu.

The news comes as India and the world is grappling with a huge increase in COVID-19 cases driven by the Omicron variant.

On Thursday, India saw the biggest single-day jump of 495 Omicron cases, taking the total number of infections of the new variant of coronavirus to 2,630, according to Union health ministry data. Of the total cases, Maharashtra has the maximum at 797, followed by Delhi at 465, Rajasthan 236, Kerala 234, Karnataka 226, Gujarat 204 and Tamil Nadu 121.

Inputs from agencies

Read all the Latest News, Trending NewsCricket News, Bollywood News,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Updated Date:

also read

India logs 3,451 new COVID-19 cases; active cases rise to 20,635
India

India logs 3,451 new COVID-19 cases; active cases rise to 20,635

The active cases comprise 0.05 per cent of the total infections, while the national COVID-19 recovery rate was recorded at 98.74 per cent, the ministry said.

WHO: China's COVID-19 plan 'unsustainable' due to highly-infectious Omicron variant
World

WHO: China's COVID-19 plan 'unsustainable' due to highly-infectious Omicron variant

The ruthless and often chaotic implementation of zero-COVID in China has stirred considerable resentment and food shortages in Shanghai, where some residents have been under lockdown for more than a month

North Korea COVID-19 outbreak: Kim Jong Un accuses officials of 'immature' in early handling in outbreak
World

North Korea COVID-19 outbreak: Kim Jong Un accuses officials of 'immature' in early handling in outbreak

North Korea's anti-virus headquarters said 62 people have died and more than 1.7 million have fallen ill amid a rapid spread of 'fever' since late April. More than a million people recovered but at least 691,170 remain in quarantine